By Jessica Johnson and Alan Mait
In the first piece of our healthcare and life sciences series, we examined the market trends shaping the sector in 2026, including renewed biotech momentum, consolidation, and the growing role of AI in the sector. But across our work with private capital investors, boards, and executive teams, the one theme that keeps coming up is execution. The tools and capital are there, but leadership is often the constraint in many situations.
In 2026, the challenge extends beyond talent scarcity. Success depends on deploying the right leaders at the right moment, with tighter capital and higher performance expectations in play. Organizations are moving away from broad team buildouts toward targeted, milestone-driven leadership hiring.
Here are the leadership talent trends we’re seeing across healthcare and life sciences in 2026.
2026 Healthcare & Life Sciences Executive Talent Trends
Founder-to-CEO transitions are accelerating.
Many privately owned companies are moving into their next phase of growth with institutional capital from venture, growth equity, private equity, or family offices. As capital becomes more selective, boards are bringing in CEOs who can professionalize and scale earlier in the lifecycle.
A study of more than 18,000 companies found that in nearly 60% of companies that go public, the founder is no longer CEO at IPO. That shift is happening sooner and more deliberately in today’s environment.
Chief Financial Officers remain one of the most competitive searches.
Limited exits and a constrained capital environment have tightened the talent pool, particularly for healthcare- and private equity-experienced CFOs.
But the role itself is evolving. In PE-backed environments, CFOs are expected to go beyond accounting and capital strategy to drive strategic value creation through integration, KPI discipline, and margin expansion.
Commercial and go-to-market leadership is surging.
Alongside operational execution, commercial and go-to-market leadership is becoming critical. Companies are investing in Chief Commercial Officers and GTM leaders who can drive organic growth.
Many healthcare businesses are stuck in low single-digit growth. Investors want leaders who can move companies to sustainable double-digit performance through strategic selling, pricing discipline, and payer-aware growth strategies, not just M&A.
Customer success is becoming revenue-critical.
Digital health and tech-enabled healthcare companies are investing in leaders focused on reducing churn and increasing customer lifetime value.
In PE-backed services and healthcare IT, customer success is increasingly tied directly to retention, contract expansion, and measurable revenue impact.
HR and People leadership is returning with a sharper mandate.
HR and people leadership are rebounding, but the focus has shifted. Organizations are prioritizing leaders who can drive workforce productivity, organizational design, and talent density, not just hiring volume.
The pace of M&A activity in biotech and pharma is not relenting.
Major recent acquisitions by Merck (Terns), Eli Lilly (Centessa), and Biogen (Apellis), along with Servier’s agreement to acquire Day One Biopharmaceuticals, signal strong intent for the remainder of the year, with other major players sitting on significant capital ready to deploy. M&A momentum is building.
This is exciting for patients, owners, and investors, and it may also represent a meaningful strategic shift in the market. The costs of manufacturing and commercial acceleration remain high, and large strategics with the know-how and built-in distribution models can offer significant value in bringing drugs to market faster.
What happens to talent absorbed into these larger companies? Are executives making their own bets and transitioning into these organizations earlier? We’re tracking this closely, but the signals suggest this is already happening.
Capital-Efficient Hiring Is Reshaping Leadership Teams
One of the most important shifts in 2026 is how companies build leadership teams.
VC-backed companies are increasingly hiring executives just-in-time around key milestones, such as clinical, product, or commercialization phases. Broad executive buildouts are often delayed until risk is reduced.
At the same time, the use of fractional and interim executives, particularly CFOs, CMOs, and COOs, is becoming a core operating model, not just a stopgap.
PE-backed companies, by contrast, are building teams around value creation plans from day one. Leadership hiring is aligned to integration, efficiency, and EBITDA growth rather than just scaling.
2026 Snapshot: What Investors & Boards Want in Leadership
Investor expectations are sharper and more execution-focused than at any point in recent years.
- Agility and adaptability. Leaders need more than one playbook and must pivot quickly as conditions change.
- A commercial mindset. Growth, margin, and value creation matter across every role and not just in sales.
- Applied AI leadership. Investor expectations around AI have matured. Executives must be able to embed AI into workflows across clinical development, operations, revenue cycle, and commercial functions, driving real ROI.
- Proven private capital experience. Boards are increasingly prioritizing leaders who’ve operated in both growth and constrained capital environments.
- Ability to scale through redesign, not just reduction. Leaders are expected not only to “do more with less,” but to rethink how work gets done.
- Regulatory and reimbursement navigation. As policy and payer dynamics become more complex, leaders who can manage regulatory risk and protect revenue are increasingly critical.
The Most Critical Roles Are Often Below the C-Suite
While CEO, CFO, and CCO roles get the most attention, many of the most important hires in 2026 sit just below the C-suite.
In life sciences, demand remains high for:
- Clinical development and CMO leadership
- Regulatory affairs and quality leaders
- Translational and biomarker strategy leaders
- Biostatistics and data science leaders
In healthcare services and tech-enabled models, key roles include:
- Revenue cycle and pricing leaders
- Value-based care and population health leaders
- Operational transformation and integration leaders
These roles often determine whether companies hit milestones or deliver investor returns.
NU + Healthcare & Life Sciences
NU has partnered with healthcare and life sciences companies and investors to place high-impact leaders. Some of our recent placements include:
- Board Director at ImmunoBrain
- Chief Executive Officer at the Cancer Research Institute
- Chief Growth Officer at Compassus
- SVP of Provider & Channel Sales at Omega Healthcare
- SVP of Global Delivery at Omega Healthcare
- Head of Finance at AllCare Georgia
- Head of Finance at Fira Health
- Chief People Officer at A Place for Mom
- Chief People Officer at Rula
- SVP of Human Resources & Administration at DAS Health
- General Counsel at Hello Heart
- General Counsel at TimelyCare
These placements reflect where the market is headed and the type of leaders investors are prioritizing heading into 2026.
Healthcare and life sciences are core to NU’s work. Searches typically close in under 85 days, driven by deep sector expertise and a highly focused approach. Our partners bring decades of experience across providers, payors, pharma, biotech, health and life sciences technology, and tech-enabled services companies. Collectively, we’ve completed hundreds of healthcare-focused searches.
What clients consistently notice is agility, directness, and precision.
- Faster paths to answers. Clients see accurate, well-vetted candidate ideas early in the search process.
- Practical use of AI. NU uses AI to drive net-new research, increase candidate flow, and scale operations, while identifying leaders who can apply AI in real operating environments.
- Transparency throughout the process. Our client portal provides 24/7 visibility into search progress.
- Operational excellence. Clients consistently highlight how smooth and efficient the search process feels compared to legacy firms.
NU Advisory Partners is an AI-native retained executive search and advisory firm focused on senior executive, operating, and board positions. If you’re interested in learning more, get in touch here.
